Triple therapy aims to boost Cancer-Free survival after surgery for HER2-Positive stomach cancer

NCT ID NCT05504720

Completed Disease control Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This phase II trial tests whether adding pembrolizumab (Keytruda) and trastuzumab (Ontruzant) to standard FLOT chemotherapy, given before and after surgery, can improve outcomes for people with HER2-positive esophagogastric adenocarcinoma. Participants receive the drug combination for up to one year, followed by surgery. The study measures how many patients are cancer-free two years after starting treatment and how many have no tumor left at the time of surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pembrolizumab, trastuzumab, and FLOT chemotherapy (docetaxel, oxaliplatin, folinic acid, fluorouracil)
What this could lead to: If successful, this combination could improve the chance of being cancer-free two years after surgery for people with HER2-positive esophagogastric cancer.
What could go wrong: This is a small, early-phase trial with no comparison group, so results may not apply broadly. The combination of drugs can cause significant side effects, and the treatment may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGOGASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGOGASTRIC ADENOCARCINOMA

Contacts and locations

Locations

Charité - Universitätsmedizin Berlin / Campus Virchow Klinikum (CVK)

Berlin, 13353, Germany
Hämatologisch-Onkologische Praxis Eppendorf

Hamburg, 20249, Germany
Institut für Klinisch-Onkologische Forschung am Krankenhaus Nordwest

Frankfurt am Main, 60488, Germany
KEM | Klinik für Internistische Onkologie gGmbH

Essen, 45136, Germany
Klinikum Nürnberg

Nuremberg, 90419, Germany
Klinikum Wolfsburg

Wolfsburg, 38440, Germany
Klinikum rechts der Isar der TU München

München, 81675, Germany
Krankenhaus Barmherzige Brüder

Regensburg, 93049, Germany
MVZ Onkologischer Schwerpunkt

Berlin, 14195, Germany
Nationales Centrum für Tumorerkrankungen

Heidelberg, 69120, Germany
St. Anna Hospital Herne

Herne, 44649, Germany
Tagestherapiezentrum (TTZ) am Interdisziplinären Tumorzentrum (ITM)

Mannheim, 68167, Germany
Universitätsklinikum Ulm

Ulm, 89070, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.